Healthcare
Medpace Holdings, Inc.(MEDP)
Live Price
Offline$460.20
+0.68% today
1Y Change
+50.00%
Window
Jun 26, 2025 โ Jun 18, 2026
- Market Cap
- $11.92B
- Revenue Growth
- +20.0%
- EPS Growth
- +19.8%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 26, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Medpace Holdings, Inc. (MEDP) is a Healthcare stock with a market cap of $11.92B and listed on NASDAQ. The stock last traded around $460.20 and up 50.0% across the available one-year price window (Jun 26, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +20.0%, EPS growth of +19.8%, a dividend yield of 0.0%. What stands out right now is revenue +20.0%, EPS +19.8%, free cash flow +19.2% with operating margin 21.0% and ROIC 56.1%. Valuation sits in the middle of the pack at P/E 25.8 and price/sales 4.5. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines MEDP price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+20.0% vs +7.6% peer median
Operating Margin
Near sector median
+21.0% vs +19.4% peer median
P/E
Below sector median
25.8 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 22, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +20.0% and EPS at +19.8%, with operating margin around 21.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -10.3% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 22, 2026 | โ | -22.6% | -18.7% | -17.0% |
2026 Feb 9, 2026 | +11.5% | -15.9% | -19.3% | -12.0% |
2025 Oct 22, 2025 | +9.3% | +9.1% | +6.9% | +8.3% |
Benchmark Edge
MEDP vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
MEDP
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
MEDP Max Drawdown
-36.61%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for MEDP and SPY.
Company Overview
Medpace Holdings, Inc.
NASDAQ Global Select
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.
- Leadership
- August James Troendle
- IPO Date
- Aug 11, 2016
- Employees
- 5.9k
- Street Address
- 5375 Medpace Way
- Mailing
- Cincinnati, OH, 45227
- Region
- Cincinnati, OH, US
- Reporting Currency
- USD
- Investor Line
- 513 579 9911
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 25.8
- EV/EBITDA
- 19.7
- Price/Sales
- 4.5
- Price/Book
- 19.9
Growth
- Revenue
- +20.0%
- EPS
- +19.8%
- Free Cash Flow
- +19.2%
Profitability
- Gross Margin
- 29.1%
- Operating Margin
- 21.0%
- Net Margin
- 17.2%
- ROE
- 120.9%
- ROIC
- 56.1%
Balance Sheet
- Debt/Equity
- 0.24
- Current Ratio
- 0.85
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.